Literature DB >> 8113684

Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes.

B Gaugler1, B Van den Eynde, P van der Bruggen, P Romero, J J Gaforio, E De Plaen, B Lethé, F Brasseur, T Boon.   

Abstract

Human melanoma cell line MZ2-MEL expresses several antigens recognized by autologous cytolytic T lymphocyte (CTL) clones. We reported previously the identification of a gene, named MAGE-1, that codes for one of these antigens named MZ2-E. We show here that antigen MZ2-D, which is present on the same tumor, is encoded by another member of the MAGE gene family named MAGE-3. Like MAGE-1, MAGE-3 is composed of three exons and the large open reading frame is entirely located in the third exon. Its sequence shows 73% identity with MAGE-1. Like MZ2-E, antigen MZ2-D is presented by HLA-A1. The antigenic peptide of MZ2-D is a nonapeptide that is encoded by the sequence of MAGE-3 that is homologous to the MAGE-1 sequence coding for the MZ2-E peptide. Competition experiments using single Ala-substituted peptides indicated that amino acid residues Asp in position 3 and Tyr in position 9 were essential for binding of the MAGE-1 peptide to HLA-A1. Gene MAGE-3 is expressed in many tumors of several types, such as melanoma, head and neck squamous cell carcinoma, lung carcinoma and breast carcinoma, but not in normal tissues except for testes. It is expressed in a larger proportion of melanoma samples than MAGE-1. MAGE-3 encoded antigens may therefore have a wide applicability for specific immunotherapy of melanoma patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8113684      PMCID: PMC2191409          DOI: 10.1084/jem.179.3.921

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  36 in total

1.  Human gene MAGE-1, which codes for a tumor-rejection antigen, is expressed by some breast tumors.

Authors:  F Brasseur; M Marchand; R Vanwijck; M Hérin; B Lethé; P Chomez; T Boon
Journal:  Int J Cancer       Date:  1992-11-11       Impact factor: 7.396

2.  The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides.

Authors:  A R Townsend; J Rothbard; F M Gotch; G Bahadur; D Wraith; A J McMichael
Journal:  Cell       Date:  1986-03-28       Impact factor: 41.582

3.  Tumor-specific cytolysis by lymphocytes infiltrating human melanomas.

Authors:  S L Topalian; D Solomon; S A Rosenberg
Journal:  J Immunol       Date:  1989-05-15       Impact factor: 5.422

4.  T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures.

Authors:  A Knuth; B Danowski; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

5.  Production of stable cytolytic T-cell clones directed against autologous human melanoma.

Authors:  M Hérin; C Lemoine; P Weynants; F Vessière; A Van Pel; A Knuth; R Devos; T Boon
Journal:  Int J Cancer       Date:  1987-03-15       Impact factor: 7.396

6.  Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation.

Authors:  E De Plaen; C Lurquin; A Van Pel; B Mariamé; J P Szikora; T Wölfel; C Sibille; P Chomez; T Boon
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

7.  Molecular cloning of the CD2 antigen, the T-cell erythrocyte receptor, by a rapid immunoselection procedure.

Authors:  B Seed; A Aruffo
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

8.  Primary stimulation by dendritic cells induces antiviral proliferative and cytotoxic T cell responses in vitro.

Authors:  S E Macatonia; P M Taylor; S C Knight; B A Askonas
Journal:  J Exp Med       Date:  1989-04-01       Impact factor: 14.307

9.  Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis.

Authors:  T Boon; J Van Snick; A Van Pel; C Uyttenhove; M Marchand
Journal:  J Exp Med       Date:  1980-11-01       Impact factor: 14.307

10.  HLA B37 determines an influenza A virus nucleoprotein epitope recognized by cytotoxic T lymphocytes.

Authors:  A J McMichael; F M Gotch; J Rothbard
Journal:  J Exp Med       Date:  1986-11-01       Impact factor: 14.307

View more
  167 in total

1.  Immune response after photodynamic therapy increases anti-cancer and anti-bacterial effects.

Authors:  Eleonora Reginato; Peter Wolf; Michael R Hamblin
Journal:  World J Immunol       Date:  2014-03-27

2.  Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.

Authors:  E Jäger; S Gnjatic; Y Nagata; E Stockert; D Jäger; J Karbach; A Neumann; J Rieckenberg; Y T Chen; G Ritter; E Hoffman; M Arand; L J Old; A Knuth
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

3.  Induction of auto-logous human cytotoxic T lymphocytes (CTL) from peripheral blood against tumor cells.

Authors:  T Ohno
Journal:  Cytotechnology       Date:  1997-01       Impact factor: 2.058

Review 4.  Lung cancer vaccines.

Authors:  Ronan J Kelly; Giuseppe Giaccone
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

5.  The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation.

Authors:  C De Smet; O De Backer; I Faraoni; C Lurquin; F Brasseur; T Boon
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

Review 6.  Immunotherapy in gastric cancer.

Authors:  Satoko Matsueda; David Y Graham
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

7.  Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1.

Authors:  Deepa Kolaseri Krishnadas; Lei Bao; Fanqi Bai; Satheesh Cheeyancheri Chencheri; Kenneth Lucas
Journal:  Tumour Biol       Date:  2014-03-02

8.  Characterization of T-cell receptors directed against HLA-A*01-restricted and C*07-restricted epitopes of MAGE-A3 and MAGE-A12.

Authors:  Shigui Zhu; Benoit J Van den Eynde; Pierre G Coulie; Yong F Li; Mona El-Gamil; Steven A Rosenberg; Paul F Robbins
Journal:  J Immunother       Date:  2012 Nov-Dec       Impact factor: 4.456

9.  Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells.

Authors:  B Mukherji; N G Chakraborty; S Yamasaki; T Okino; H Yamase; J R Sporn; S K Kurtzman; M T Ergin; J Ozols; J Meehan
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

10.  Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells.

Authors:  Djordje Atanackovic; York Hildebrandt; Adam Jadczak; Yanran Cao; Tim Luetkens; Sabrina Meyer; Sebastian Kobold; Katrin Bartels; Caroline Pabst; Nesrine Lajmi; Maja Gordic; Tanja Stahl; Axel R Zander; Carsten Bokemeyer; Nicolaus Kröger
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.